fashion -WSS

fashion

author：fashion 2025-09-30 18:00:41 - browse：5176

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： New oral drug delivery patch is modeled after octopus tentacles

focus

WSS

Some top drug companies are starting to take action on climate

At JPM 2024, hospital systems pitch financial strength to investors

Boston Scientific acquires urology company Axonics for $3.7 billion

Does Paxlovid work in people vaccinated against Covid

Flu, Covid vaccination rates decline, new survey data show

Setback for rare diseases as Taysha Gene Therapies pulls back

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

In Memoriam: Notable people who died in 2023

STAT Virtual Event: JPM Recap, Live!

DIEP, the 'gold standard' of breast reconstruction, is under threat

New oral drug delivery patch is modeled after octopus tentacles

Anesthesiologist group: stop taking Ozempic before surgery

JPM pitch from hospitals? Revenue streams outside of patient care

Alkermes shareholders re

Arena BioWorks launches in Cambridge to speed drug discovery

explore

Medicare innovation center doesn’t save money, experts say

Merck to acquire Harpoon Therapeutics for $680 million

Nonprofit, backed by Microsoft, to certify AI tools in health care

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Flu, Covid vaccination rates decline, new survey data show

knowledge

focus

focus

entertainment